OVTOKOHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 15 publications

Quick Overview

Ovarian clear cell adenocarcinoma cell line with PIK3CA mutation and chemoresistance traits.

Detailed Summary

OVTOKO is a human ovarian clear cell adenocarcinoma cell line established from a solid metastatic tumor. It exhibits a polygonal morphology and grows in monolayers without contact inhibition. The cell line has a low proliferation rate and demonstrates resistance to platinum-based chemotherapy, with an IC50 for cisplatin of 12.2 μM. OVTOKO harbors a PIK3CA mutation at codon 542 (E542K), which is associated with activation of the PI3K/Akt signaling pathway. This cell line is valuable for studying the molecular mechanisms of chemoresistance and for developing targeted therapies in clear cell ovarian cancer.

Research Applications

Investigation of PI3K/Akt pathway activation in chemoresistanceStudy of PIK3CA mutations in ovarian cancerDevelopment of targeted therapies for clear cell ovarian cancer

Key Characteristics

PIK3CA mutation (E542K)Resistance to platinum-based chemotherapyLow proliferation rateExpression of cytokeratins 7, 8, 18, and 19
Generated on 6/19/2025

Basic Information

Database IDCVCL_3117
SpeciesHomo sapiens (Human)
Tissue SourceSpleen[UBERON:UBERON_0002106]

Donor Information

Age78
Age CategoryAdult
SexFemale
Raceasian

Disease Information

DiseaseClear cell adenocarcinoma of the ovary
LineageOvary/Fallopian Tube
SubtypeClear Cell Ovarian Cancer
OncoTree CodeCCOV

DepMap Information

Source TypeHSRRB
Source IDACH-000663_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
8,12
D16S539
11,12
D18S51
19
D21S11
29,31
D3S1358
15
D5S818
11,12
D7S820
9,10
D8S1179
10,14
FGA
21,23
Penta D
9,10
Penta E
14
TH01
6,9.3
TPOX
8,12
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Kigawa J., Harada T.

Hum. Cell 26:121-127(2013).

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Miyazaki K.

Hum. Pathol. 43:2197-2206(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";

Anderson M.L., Matzuk M.M.

Mol. Endocrinol. 24:447-463(2010).

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Hirohashi S., Inazawa J., Imoto I.

Cancer Res. 67:7095-7105(2007).

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.

Hirahara F., Shirotake S.

Cancer Lett. 162:39-48(2001).

Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.

Kitamura H., Minaguchi H.

Br. J. Cancer 76:829-835(1997).

Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.

Minaguchi H.

Gynecol. Oncol. 57:33-46(1995).

Web Resources